Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 6Terminated 1

Sponsor Class

OTHER 10INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1bafetinib 1Mycobacterium w vaccine 1Docetaxel 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Hormone Refractory Prostate Cancer × Clear all
NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Bayer

Phase 2 Completed
100 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00477529 2019-11-22

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Celgene

Phase 1/2 Completed
102 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Amgen

Phase 3 Completed
1,435 enrolled 15 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed
23 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡